Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WAVE T1D
NCT07061574Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- Mar 2026
- Primary completion
- Apr 2030
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of adalimumab, verapamil in type 1 diabetes mellitus (T1D), sponsored by City of Hope. Started Mar 2026; status: recruiting.
02
Drugs
adalimumabverapamil
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT07061574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07061574.